Focused Alpha LLC Makes New $1.34 Million Investment in CVS Health Corporation $CVS

Focused Alpha LLC purchased a new position in CVS Health Corporation (NYSE:CVS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 12,923 shares of the pharmacy operator’s stock, valued at approximately $1,337,000.

A number of other institutional investors and hedge funds have also made changes to their positions in CVS. BlackRock Inc. acquired a new stake in CVS Health during the second quarter worth about $12,747,462,000. Vanguard Group Inc. lifted its position in shares of CVS Health by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after purchasing an additional 1,824,424 shares in the last quarter. State Street Corp boosted its position in CVS Health by 2.1% in the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock valued at $4,776,182,000 after buying an additional 1,245,457 shares during the last quarter. Capital International Investors increased its holdings in CVS Health by 3.4% during the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after purchasing an additional 900,153 shares during the last quarter. Finally, Norges Bank acquired a new stake in CVS Health in the fourth quarter valued at $1,666,265,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the company. Truist Financial upped their price objective on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Robert W. Baird set a $107.00 target price on CVS Health in a research report on Thursday, August 6th. UBS Group upped their target price on CVS Health from $122.00 to $126.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Morgan Stanley raised their price objective on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Finally, DA Davidson lifted their price target on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and an average target price of $106.75.

Insider Transactions at CVS Health

In related news, Director Larry Robbins sold 1,018,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $93.82, for a total transaction of $95,508,760.00. Following the transaction, the director owned 5,195,261 shares of the company’s stock, valued at approximately $487,419,387.02. The trade was a 16.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.85% of the company’s stock.

CVS Health Price Performance

Shares of NYSE:CVS opened at $93.99 on Tuesday. The stock has a market capitalization of $120.21 billion, a P/E ratio of 24.87, a P/E/G ratio of 0.93 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The business has a 50-day moving average of $102.46 and a two-hundred day moving average of $88.41. CVS Health Corporation has a fifty-two week low of $69.40 and a fifty-two week high of $110.68.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. During the same quarter last year, the company posted $1.81 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, equities research analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. CVS Health’s dividend payout ratio (DPR) is 70.37%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.